Found 7 matching trials
Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus
PHASE2This study is expected to demonstrate the anti-diabetic efficacy of 3-month...
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
PHASE2The study was being conducted in order to assess the pharmacokinetics and t...
Location
University of California
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
PHASE3The participants of this study will have confirmed Primary Biliary Cholangi...
Status
Active Not Recruiting
Location
The Institute for Liver Health
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
PHASE2The purpose of this study is to demonstrate the efficacy on insulin sensiti...
Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity
PHASE2The purpose of this study is to evaluate the efficacy of GFT505 80mg in red...
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
PHASE2The purpose of this study is to evaluate the efficacy of GFT505 80mg compar...
Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
PHASE2Abdominal obesity and type-2 Diabetes are associated with chronic liver dis...